Who founded Ambagon Therapeutics?

Ambagon Therapeutics was founded by Christian Ottmann in 2020.

Who are Ambagon Therapeutics's investors?

Ambagon Therapeutics's investors include Droia Ventures, Mission Biocapital, MRL Ventures Fund, Nextech Invest, Inkef, RA Capital, Syncona.

How much funding has Ambagon Therapeutics raised?

Ambagon Therapeutics has disclosed $55.4M raised across 3 rounds.

Where is Ambagon Therapeutics headquartered?

Ambagon Therapeutics is headquartered in Eindhoven, US.

Ambagon Therapeutics

Eindhoven, US · Founded 2020 · Delaware corporation · 15 employees on LinkedIn · 7 known investors

Find your way into Ambagon Therapeutics

70 people in our graph share verified history with the Ambagon Therapeutics team — schools, employers, funds. One of them is your warm intro.

Christian Schubertunlockedknows Christian Ottmann · together at Ambagon Therapeutics (overlapped)

knows the team · via Ambagon Therapeutics

×10knows the team · via Eindhoven University of Technology

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

Biotech Deep Tech Medical Devices

Founders & leadership

Ambagon Therapeutics was founded in 2020 by Christian Ottmann.

Christian Ottmann inCo-Founder, CSOChristian Ottmann is an Associate Professor of Molecular Cell and Structural Biology at Technische Universiteit Eindhoven, with expertise in chemical biology. He co-founded Ambagon Therapeutics, which develops small molecule stabilizers of 14-3-3 protein complexes for therapeutic applications.

Josh SeidenfeldExecutive

Michelle ArkinNamed on SEC filing

Nancy PryerNamed on SEC filing

Margarita ChavezNamed on SEC filing

Bryan MillerNamed on SEC filing

Adam RosenberginChair2020–2025Executive Officer, Director at Rodin Therapeutics

Scott ClarkeinAdvisor2024–2024Chief Executive Officer at CatalYm

Board

Melissa McCrackenBoard Member2022–2026Partner at Nextech Invest

Peter Dudek in 𝕏Board Director2020–2024President at MRL Ventures Fund

Janwillem NaesensBoard directorManaging Partner at Droia Ventures

Roel Bulthuis inBoard directorInvestor at Syncona

Investors · 7

Droia VenturesLeuven · $540Kvia Janwillem Naesens · board

Mission BiocapitalSan Francisco · $500K

MRL Ventures FundCambridge · $25M

Nextech InvestZurich · $648K – $3.2M

Inkefreported · 2 sourcesAmsterdam

RA Capitalreported · 2 sourcesBoston

SynconareportedLondonvia Roel Bulthuis · board

Reported raises · per SEC filings

Form D private placements

$55.4M disclosed across 3 rounds · 2021–2025

▶$5MraisedFeb 2025 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Melissa McCrackenDirector
Josh SeidenfeldExecutive Officer
Christian OttmannExecutive Officer

Offering amount: $12M
Amount sold: $5M
First sale: Jan 2025
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$45MraisedJun 2022 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Josh SeidenfeldExecutive Officer
Michelle ArkinDirector
Peter DudekDirector
Roel BulthuisDirector
Janwillem NaesensDirector
Margarita ChavezDirector
Nancy PryerExecutive Officer
Christian OttmannExecutive Officer
Adam RosenbergDirector
Melissa McCrackenDirector
Bryan MillerExecutive Officer
Scott ClarkeExecutive Officer, Director

Offering amount: $85M
Amount sold: $45M
First sale: Jan 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.4MraisedDec 2021 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michelle ArkinDirector
Nancy PryerExecutive Officer
Christian OttmannExecutive Officer
Margarita ChavezDirector
Peter DudekDirector
Janwillem NaesensDirector
Bryan MillerExecutive Officer
Roel BulthuisDirector
Adam RosenbergDirector
Josh SeidenfeldExecutive Officer
Scott ClarkeExecutive Officer, Director

Offering amount: $5.4M
Amount sold: $5.4M
First sale: Dec 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

San Francisco California based Ambagon Therapeutics is raising $84,999,994.00 in New Equity Investment. - intelligence360intelligence360.news · Jun 2022

Biotech startup Ambagon Therapeutics raises €75.1M from Amsterdam-based Inkef Capital, others - Silicon Canalssiliconcanals.com · Jan 2022

New Biotech Earns $85 Million in Series A Funding - BioSpacebiospace.com · Jan 2022

Ambagon Therapeutics Launches with $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline – Droia Ventures – Investing in Impactdroiaventures.com · Jan 2022

Ambagon Therapeutics Raises $85M in Series A Funding - FinSMEsfinsmes.com · Jan 2022

Frequently asked questions

What does Ambagon Therapeutics do?: Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
Who founded Ambagon Therapeutics?: Ambagon Therapeutics was founded by Christian Ottmann in 2020.
Who are Ambagon Therapeutics's investors?: Ambagon Therapeutics's investors include Droia Ventures, Mission Biocapital, MRL Ventures Fund, Nextech Invest, Inkef, RA Capital, Syncona.
How much funding has Ambagon Therapeutics raised?: Ambagon Therapeutics has disclosed $55.4M raised across 3 rounds.
Where is Ambagon Therapeutics headquartered?: Ambagon Therapeutics is headquartered in Eindhoven, US.